PTAB: Roche patent can’t evade IPR under Fintiv

Roche unit Chugai failed to persuade the US Patent Trial and Appeal Board (PTAB) that it should not institute inter partes reviews (IPRs) of a patent covering Actemra (Atlizumab), a treatment for arthritis under the NHK/Fintiv rule.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Mylan throws down new gauntlet in Novo Wegovy patent fight

25 September 2026 Another Wegovy patent has been drawn into the long-running dispute between Mylan and Novo Nordisk over proposed generic versions of the weight-loss drug.

Pharma

Novartis defeats Orange Book challenge but suffers EU setback

24 September 2026 An Entresto Orange Book listing has survived a challenge in the US, while two trademark disputes handed Novartis contrasting fortunes at a European court.

Pharma

Behind the case: How Novartis defended its blockbuster Entresto in the UK

22 September 2026 After a run of UK decisions going against major pharma patents on plausibility, Novartis bucked the trend with Entresto. The company’s lead counsel from Bristows explains why and what patentees can take from the ruling.

More features

Mylan throws down new gauntlet in Novo Wegovy patent fight

Novartis defeats Orange Book challenge but suffers EU setback

New UK High Court judge named as replacement for Justice Meade

US firm hires litigation pro whose clients include Pfizer, Medtronic

Behind the case: How Novartis defended its blockbuster Entresto in the UK

Oxford Nanopore scores urgent injunction at UPC in DNA sequencing fight

Benesch adds former McDermott IP practice head

Leading European patent litigator to join Carpmaels & Ransford

PTAB: Roche patent can’t evade IPR under Fintiv

More on this story

Editor's picks

Editor's picks

More features